Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23933144 | 0.84 | — | — | |
| SCHEMBL9513775 | 0.67 | ACACB (0.38) | — | |
| SCHEMBL28864322 | 0.66 | CYP3A4 (0.49) | — | |
| SCHEMBL29067310 | 0.66 | ALDH1A1 (0.47) | — | |
| SCHEMBL29182966 | 0.66 | MEN1 (0.39) | PARP1BTK | |
| SCHEMBL29067332 | 0.65 | ALDH1A1 (0.50) | — | |
| SCHEMBL23933145 | 0.64 | KMT2A (0.35) | — | |
| SCHEMBL23850698 | 0.63 | THRB (0.33) | — | |
| SCHEMBL28849760 | 0.62 | PARP1 (0.40) | PARP1 | |
| SCHEMBL28723873 | 0.62 | KMT2A (0.40) | PARP1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4271387-A1 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCS CONTAINING AND USE THEREOF | Immunext, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| CN-117015381-A | Novel steroid payloads, steroid linkers, ADCs containing the same and uses thereof | 伊穆奈克斯特股份有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20230310634-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | IMMUNEXT INC (US) | 2023-10-05 | — | — | US | disclosed |
| CN-116096413-A | Anti-human VISTA antibodies and uses thereof | 伊穆奈克斯特股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4136118-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | Immunext, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2022150637-A1 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF | IMMUNEXT, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2021216913-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | IMMUNEXT, INC. (US) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310634-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | CD47, CLTA, FCGR2A | PARP1 3306/4885BTK 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.